A study of an experimental drug for pulmonary arterial hypertension
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pulmonary arterial hypertension (PAH) by a doctor.
- Your PAH causes some limitation in physical activity, such as feeling tired or short of breath during daily activities (WHO functional class II or III).
- You are already on stable treatment for PAH and your doses have not changed recently.
- You can walk between 150 and 550 meters in 6 minutes, measured twice during screening.
- You do not have other types of pulmonary hypertension caused by heart or lung disease, blood clots, or other conditions.
- You have not had any bleeding in your brain or increased pressure in your head in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IMC-003 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can help improve symptoms and exercise ability when added to your current PAH medications.
This trial tests a combination of three medications (an endothelin receptor antagonist, a PDE5 inhibitor, and sotatercept) as the first treatment for people newly diagnosed with pulmonary arterial hypertension (PAH). It aims to see if starting with all three together works better than the usual approach.
This study tests a drug called ambrisentan for people with very early, low-risk pulmonary arterial hypertension (PAH). If you have a mild form of PAH and haven't yet taken other PAH medications, this trial might help slow the progression of your condition.
This trial tests whether adding the study drug sotatercept to your current PAH therapy along with a home exercise program can help you feel better and be more active. It's for people with certain types of PAH who are stable on their current treatment.
This study tests a new pill, ROC-101, for people with pulmonary hypertension (high blood pressure in the lungs). It aims to see if the pill can improve symptoms and daily function.
This trial tests whether adding a new drug called tiprelestat to standard pulmonary arterial hypertension (PAH) treatments can help patients breathe better and feel stronger. You'd receive tiprelestat or placebo along with your current PAH medications.
Hear when a new Pulmonary Arterial Hypertension (PAH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.